TrovaGene, Inc. (TROV) Lowered to “Hold” at Maxim Group

TrovaGene, Inc. (NASDAQ:TROV) was downgraded by investment analysts at Maxim Group from a “buy” rating to a “hold” rating in a report released on Wednesday.

TROV has been the topic of several other research reports. set a $4.00 price target on TrovaGene and gave the stock a “buy” rating in a research note on Tuesday, August 22nd. restated an “overweight” rating on shares of TrovaGene in a research note on Tuesday, August 8th.

TrovaGene (NASDAQ TROV) opened at $0.65 on Wednesday. TrovaGene has a twelve month low of $0.61 and a twelve month high of $3.30.

TrovaGene (NASDAQ:TROV) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. The company had revenue of $0.12 million for the quarter. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.themarketsdaily.com/2017/11/15/trovagene-inc-trov-lowered-to-hold-at-maxim-group-2.html.

Institutional investors have recently bought and sold shares of the stock. LMR Partners LLP purchased a new stake in shares of TrovaGene in the 2nd quarter worth approximately $151,000. Susquehanna International Group LLP grew its stake in shares of TrovaGene by 2,781.0% in the 2nd quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock worth $174,000 after buying an additional 133,240 shares during the last quarter. KCG Holdings Inc. lifted its position in TrovaGene by 560.1% in the 1st quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock valued at $242,000 after acquiring an additional 178,440 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in TrovaGene by 1,079.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock valued at $351,000 after acquiring an additional 254,601 shares in the last quarter. Institutional investors own 9.05% of the company’s stock.

About TrovaGene

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply